With Enbrel patent victory, Amgen scores major win against biosims—and Sandoz takes a big loss

Discussion in 'Novartis' started by anonymous, Aug 16, 2019 at 10:53 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest


  2. anonymous

    anonymous Guest

    Oh come on. We still might get the blockbuster peg filgrastim

    And we are killing it with our phone app for opioid addiction. Killing it!

    We have given away so many trinkets and gift cards to those who use it.

    WE ARE ONE HECK OF A SANDOZ
     
  3. anonymous

    anonymous Guest

    But - let’s make an agreement to manufacture an API that competes with a product from Amgen that we co-promote such that we can keep things interesting.
     
  4. anonymous

    anonymous Guest

    Yea sandoz is about to be dissolved. BioPharma failure majorly
     
  5. anonymous

    anonymous Guest

    My oncology customers laugh at me. They say every time I see you sandoz has bad news in the press. What’s up with you guys?
     
  6. anonymous

    anonymous Guest

    If Sandoz were asked to make generic saltines I think they would botch that up
     
  7. anonymous

    anonymous Guest

    Oh boy peg filgrastim. Oh boy oh boy. Contract play.

    When’s your big late to market peg coming?

    Oh then you have the epi pen. Oh boy oh boy. Nothing that would keep Field more employed but you got it. Two buy ins a year.

    You go sandoz. Stand proud. Stand like a woman. You are one super duper sandoz
     
  8. anonymous

    anonymous Guest

    The only people still present here at sandoz onc are ones that can’t get hired any where else or neee their time of service to hit a vested mark.

    There is absolutely no work being done at all!